Mir 145/143: tumor suppressor, oncogenic microenvironmental factor or ...both?
作者信息
Cioce Mario, Strano Sabrina, Muti Paola, Blandino Giovanni
机构信息
Oncogenomic and Epigenetic Unit, Regina Elena, National Cancer Institute, Rome, 00144 Italy.
Department of Oncology, Juravinski Cancer Center-McMaster University, Hamilton, Ontario, Canada.
出版信息
Aging (Albany NY). 2016 May;8(5):1153-5. doi: 10.18632/aging.100965.
Abstract
摘要
相似文献
1
Mir 145/143: tumor suppressor, oncogenic microenvironmental factor or ...both?
Aging (Albany NY). 2016 May;8(5):1153-5. doi: 10.18632/aging.100965.
2
MicroRNAs Determining Carcinogenesis by Regulating Oncogenes and Tumor Suppressor Genes During Cell Cycle.
Microrna. 2020;9(2):82-92. doi: 10.2174/2211536608666190919161849.
3
OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer.
Cancer Res. 2016 Jul 1;76(13):3666-70. doi: 10.1158/0008-5472.CAN-16-0359. Epub 2016 Jun 20.
4
Towards an extension of the two-variable model of carcinogenesis through oncogenes and tumour suppressor genes.
Med Hypotheses. 2011 Dec;77(6):956-8. doi: 10.1016/j.mehy.2011.08.017. Epub 2011 Sep 7.
5
MiR-211 plays a dual role in cancer development: From tumor suppressor to tumor enhancer.
Cell Signal. 2023 Jan;101:110504. doi: 10.1016/j.cellsig.2022.110504. Epub 2022 Oct 26.
6
MiR-205 functions as a tumor suppressor in adenocarcinoma and an oncogene in squamous cell carcinoma of esophagus.
Tumour Biol. 2016 Jun;37(6):8007-18. doi: 10.1007/s13277-015-4656-8. Epub 2015 Dec 28.
7
A comprehensive search for microRNAs with expression profiles modulated by oncogenic KRAS: potential involvement of miR-31 in lung carcinogenesis.
Oncol Rep. 2014 Oct;32(4):1374-84. doi: 10.3892/or.2014.3339. Epub 2014 Jul 18.
8
MicroRNAs as novel targets and tools in cancer therapy.
Cancer Lett. 2017 Feb 28;387:84-94. doi: 10.1016/j.canlet.2016.03.043. Epub 2016 Apr 1.
9
Integrated Genomics Identifies miR-32/MCL-1 Pathway as a Critical Driver of Melanomagenesis: Implications for miR-Replacement and Combination Therapy.
PLoS One. 2016 Nov 15;11(11):e0165102. doi: 10.1371/journal.pone.0165102. eCollection 2016.
10
Targeting miR-205 in breast cancer.
Expert Opin Ther Targets. 2009 Dec;13(12):1439-48. doi: 10.1517/14728220903338777.
引用本文的文献
1
The NcRNA/Wnt axis in lung cancer: oncogenic mechanisms, remarkable indicators and therapeutic targets.
J Transl Med. 2025 Mar 14;23(1):326. doi: 10.1186/s12967-025-06326-4.
2
Therapeutic delivery of microRNA-143 by cationic lipoplexes for non-small cell lung cancer treatment in vivo.
J Cancer Res Clin Oncol. 2019 Dec;145(12):2951-2967. doi: 10.1007/s00432-019-03051-6. Epub 2019 Oct 25.
3
Multipronged activity of combinatorial miR-143 and miR-506 inhibits Lung Cancer cell cycle progression and angiogenesis in vitro.
Sci Rep. 2018 Jul 12;8(1):10495. doi: 10.1038/s41598-018-28872-2.
4
MiR-145 inhibits the epithelial-to-mesenchymal transition via targeting ADAM19 in human glioblastoma.
Oncotarget. 2017 Sep 30;8(54):92545-92554. doi: 10.18632/oncotarget.21442. eCollection 2017 Nov 3.
5
MicroRNAs-143 and -145 induce epithelial to mesenchymal transition and modulate the expression of junction proteins.
Cell Death Differ. 2017 Oct;24(10):1750-1760. doi: 10.1038/cdd.2017.103. Epub 2017 Jun 23.
6
miR-143 and miR-145 disrupt the cervical epithelial barrier through dysregulation of cell adhesion, apoptosis and proliferation.
Sci Rep. 2017 Jun 8;7(1):3020. doi: 10.1038/s41598-017-03217-7.
7
RNA-binding protein RBM3 prevents NO-induced apoptosis in human neuroblastoma cells by modulating p38 signaling and miR-143.
Sci Rep. 2017 Jan 30;7:41738. doi: 10.1038/srep41738.
本文引用的文献
1
The miR-143/miR-145 cluster and the tumor microenvironment: unexpected roles.
Genome Med. 2016 Mar 17;8(1):29. doi: 10.1186/s13073-016-0284-1.
2
Stromal Expression of miR-143/145 Promotes Neoangiogenesis in Lung Cancer Development.
Cancer Discov. 2016 Feb;6(2):188-201. doi: 10.1158/2159-8290.CD-15-0854. Epub 2015 Nov 19.
3
Epigenetic silencing of miR-145-5p contributes to brain metastasis.
Oncotarget. 2015 Nov 3;6(34):35183-201. doi: 10.18632/oncotarget.5930.
4
Implications of miR cluster 143/145 as universal anti-oncomiRs and their dysregulation during tumorigenesis.
Cancer Cell Int. 2015 Sep 29;15:92. doi: 10.1186/s12935-015-0247-4. eCollection 2015.
5
Computational analysis of cell-to-cell heterogeneity in single-cell RNA-sequencing data reveals hidden subpopulations of cells.
Nat Biotechnol. 2015 Feb;33(2):155-60. doi: 10.1038/nbt.3102. Epub 2015 Jan 19.
6
Downregulation of microRNAs 145-3p and 145-5p is a long-term predictor of postmenopausal breast cancer risk: The ORDET prospective study.
Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2471-81. doi: 10.1158/1055-9965.EPI-14-0398. Epub 2014 Jul 29.
7
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma.
Science. 2014 Jun 20;344(6190):1396-401. doi: 10.1126/science.1254257. Epub 2014 Jun 12.
8
MicroRNA expression profiling of thymic epithelial tumors.
Lung Cancer. 2014 Aug;85(2):197-204. doi: 10.1016/j.lungcan.2014.04.008. Epub 2014 Apr 29.
9
miR-145 inhibits migration and invasion of glioma stem cells by targeting ABCG2.
Neuromolecular Med. 2014 Jun;16(2):517-28. doi: 10.1007/s12017-014-8305-y. Epub 2014 Apr 29.
10
Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101.
Ann Hematol. 2014 Jun;93(6):983-93. doi: 10.1007/s00277-014-2021-4. Epub 2014 Feb 28.
Zotero 插件